Drug Trial Radar · NCT07566052
A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
356
Planned (sponsor's estimate)
Start
Aug 19, 2026
Primary completion
Jun 30, 2030
Study completion Jun 30, 2030
Sponsor
- Lead sponsor
- Astellas Pharma Global Development, Inc.Astellas (ALPMY)
- Sponsor type
- Industry
- First posted
- May 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. The first treatment is usually chemotherapy, given with another treatment that targets specific proteins on cancer cells. If the cancer gets worse, the next main treatment is usually a medicine called docetaxel. This treatment doesn't stop most people's cancer from getting worse for very long. Other treatments are needed to improve outcomes in people with NSCLC. Genes give your body instructions on how to make proteins. Proteins are needed to keep the body working properly. Many types of cancer are caused by changes in certain genes, making them faulty. Many people with NSCLC have a faulty KRAS gene in their tumor. One such change in the KRAS gene is called a G12D mutation. Researchers are looking for ways to stop the actions of abnormal proteins made from the KRAS G12D mutation. Setidegrasib (ASP3082) is thought to remove some of the abnormal proteins made from the faulty KRAS gene. Before setidegrasib can become available as a treatment, studies need to be done. This study is for people with NSCLC with a faulty KRAS gene in their tumor. In this study, some people will be given setidegrasib and some people will be given docetaxel. The main aims are to learn how long people who are given setidegrasib live with cancer without it getting worse, compared to people who are given docetaxel, and if they live for longer. Other aims are to check tumor response, symptoms, how the body processes setidegrasib, and its safety, compared with docetaxel. The main aims of study are to learn how long people who are given setidegrasib live with cancer without it getting worse, compared to people who are given docetaxel and if people who are given setidegrasib live for longer compared to people who are given docetaxel. People in this study will be adults with locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) with the G12D mutation in their KRAS gene. Locally advanced means the cancer has spread to nearby tissue. Unresectable means the cancer cannot be removed by surgery. Metastatic means the cancer has spread to other parts of the body. They have had no more than 2 previous treatments for their cancer. The key reasons people cannot take part are if they have different faulty genes in their tumor which can be targeted with other treatments, have symptomatic or untreated cancers that have spread from the lung into the brain or nervous system, their cancer has spread to the thin tissue that covers the brain and spinal cord (leptomeningeal disease), or they have recently had other active cancers that required treatment. In this study, people will either receive setidegrasib or docetaxel. Whether people receive setidegrasib or docetaxel is decided by chance, not by the study doctor. Both study treatments are given slowly through a tube into a vein (infusion). People will continue to receive study treatment until their cancer gets worse, they can't tolerate the study treatment, they start other cancer treatment, they or the doctor decides the person should stop receiving study treatment, or sadly, they pass away. Some people on docetaxel may be able to switch to setidegrasib during the study if their cancer becomes worse. There will be safety checks at each visit, and the doctors will continue to check for medical problems and people's wellbeing throughout the study. People will continue to have scans of their tumor every 6 weeks for the first year, then every 9 weeks until their cancer becomes worse. After people's cancer becomes worse, clinic staff will telephone people every 12 weeks to check on their cancer.
Conditions
- Non-small Cell Lung Cancer (NSCLC)
Interventions
SetidegrasibDrug
Intravenous infusion
DocetaxelDrug
Intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. as assessed by blinded independent central review (BICR)Time frame: Up to 2.3 years
- Overall Survival (OS)Time frame: Up to 4.2 years
Locations
30 sites in 3 countries. Site status is shown where the registry gives one.
Oncura Health d.b.a.Los Angeles Cancer Network
Glendale, California · Recruiting
UCLA Health - Santa Monica Cancer Care
Los Angeles, California · Recruiting
UCSF Health - UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California · Recruiting
Baptist Health - Boca Raton Regional Hospital
Boca Raton, Florida · Recruiting
Astera Cancer Care
Edison, New Jersey · Recruiting
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey · Recruiting
Texas Oncology-Longview Cancer Center
Longview, Texas · Recruiting
Virginia Cancer Specialists
Arlington, Virginia · Recruiting
Chongqing Cancer Hospital
Chongqing, Chongqing Municipality, China · Recruiting
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, China · Recruiting
Sun Yat-sen University Cancer Center
Guangzhou, Huangpu District, China · Recruiting
The Affiliated Hospital of Inner Mongolia Medical University
Hohhot, Inner Mongolia, China · Recruiting
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China · Recruiting
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China · Recruiting
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Shangcheng District, China · Recruiting
The First Hospital of Shanxi Medical University
Taiyuan, Shanxi, China · Recruiting
Sichuan Cancer Hospital & Institute
Chengdu, Sichuan, China · Recruiting
Sun Yat-sen University Cancer Center
Guangzhou, Yuexiu District, China · Recruiting
Kyushu Cancer Center
Fukuoka, Fukuoka, Japan · Recruiting
Hiroshima City Hiroshima Citizens Hospital
Hiroshima, Hiroshima, Japan · Recruiting
Hokkaido University Hospital
Sapporo, Hokkaido, Japan · Recruiting
Hyogo Cancer Center
Akashi, Hyōgo, Japan · Recruiting
Kanagawa Prefectural Hospital - Kanagawa Cancer Center
Yokohama, Kanagawa, Japan · Recruiting
Japanese Foundation for Cancer research
Tokyo, Koto-ku, Japan · Recruiting
Miyagi Cancer Center
Natori-shi, Miyagi, Japan · Recruiting
Niigata Cancer Center Hospital
Niigata, Niigata, Japan · Recruiting
Kansai Medical University Hospital
Hirakata, Osaka, Japan · Recruiting
Kindai University Hospital
Sakai, Osaka, Japan · Recruiting
Shizuoka Cancer Center
Nagaizumi-cho, Sunto-gun, Shizuoka, Japan · Recruiting
Tokyo Metropolitan Hospital
Bunkyo-ku, Tokyo, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.